CABALETTA BIO INC's ticker is CABA and the CUSIP is 12674W109. A total of 61 filers reported holding CABALETTA BIO INC in Q3 2021. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $10,531,660 | +62.3% | 691,872 | +37.6% | 0.00% | 0.0% |
Q2 2023 | $6,490,205 | +257.0% | 502,727 | +128.7% | 0.00% | – |
Q1 2023 | $1,818,159 | +84900.4% | 219,850 | -4.9% | 0.00% | – |
Q4 2022 | $2,139 | -97.5% | 231,265 | +78.6% | 0.00% | – |
Q3 2022 | $84,000 | -38.7% | 129,480 | 0.0% | 0.00% | – |
Q2 2022 | $137,000 | -44.8% | 129,480 | +5.6% | 0.00% | – |
Q1 2022 | $248,000 | -46.6% | 122,605 | -0.0% | 0.00% | – |
Q4 2021 | $464,000 | -67.8% | 122,606 | +3.3% | 0.00% | – |
Q3 2021 | $1,442,000 | +42.6% | 118,640 | +0.8% | 0.00% | – |
Q2 2021 | $1,011,000 | -54.9% | 117,662 | -41.8% | 0.00% | – |
Q1 2021 | $2,243,000 | +2.0% | 202,144 | +14.7% | 0.00% | – |
Q4 2020 | $2,200,000 | +22.0% | 176,308 | +5.9% | 0.00% | – |
Q3 2020 | $1,804,000 | -12.3% | 166,455 | -9.9% | 0.00% | – |
Q2 2020 | $2,057,000 | +90.3% | 184,700 | +24.6% | 0.00% | – |
Q1 2020 | $1,081,000 | -65.1% | 148,208 | -33.1% | 0.00% | – |
Q4 2019 | $3,094,000 | – | 221,548 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lynx1 Capital Management LP | 2,106,000 | $32,053,320 | 21.20% |
COMMODORE CAPITAL LP | 2,525,753 | $38,441,961 | 4.49% |
Bain Capital Life Sciences Investors, LLC | 2,000,000 | $30,440,000 | 3.40% |
VR Adviser, LLC | 1,973,253 | $30,032,911 | 3.16% |
Cormorant Asset Management, LP | 2,879,424 | $43,824,833 | 2.56% |
Velan Capital Investment Management LP | 150,000 | $2,283,000 | 1.84% |
Redmile Group, LLC | 1,774,252 | $27,004,115 | 1.28% |
TCG Crossover Management, LLC | 486,795 | $7,409,020 | 1.09% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,340,118 | $35,616,596 | 0.78% |
Integral Health Asset Management, LLC | 330,000 | $5,022,600 | 0.70% |